These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38423224)

  • 1. Understanding Relative Biological Effectiveness and Clinical Outcome of Prostate Cancer Therapy Using Particle Irradiation: Analysis of Tumor Control Probability With the Modified Microdosimetric Kinetic Model.
    Besuglow J; Tessonnier T; Mein S; Eichkorn T; Haberer T; Herfarth K; Abdollahi A; Debus J; Mairani A
    Int J Radiat Oncol Biol Phys; 2024 Aug; 119(5):1545-1556. PubMed ID: 38423224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inclusion of a variable RBE into proton and photon plan comparison for various fractionation schedules in prostate radiation therapy.
    Ödén J; Eriksson K; Toma-Dasu I
    Med Phys; 2017 Mar; 44(3):810-822. PubMed ID: 28107554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosimetric considerations to determine the optimal technique for localized prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-dose-rate brachytherapy.
    Georg D; Hopfgartner J; Gòra J; Kuess P; Kragl G; Berger D; Hegazy N; Goldner G; Georg P
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):715-22. PubMed ID: 24521685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a prospective randomized trial on long-term effectiveness of protons and carbon ions in prostate cancer: LEM I and α/β = 2 Gy overestimates the RBE.
    Eichkorn T; Karger CP; Brons S; Koerber SA; Mielke T; Haberer T; Debus J; Herfarth K
    Radiother Oncol; 2022 Aug; 173():223-230. PubMed ID: 35714806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RBE-weighted dose in carbon ion therapy for ACC patients: Impact of the RBE model translation on treatment outcomes.
    Molinelli S; Bonora M; Magro G; Casale S; Dale JE; Fossati P; Hasegawa A; Mirandola A; Ronchi S; Russo S; Preda L; Valvo F; Orecchia R; Ciocca M; Vischioni B
    Radiother Oncol; 2019 Dec; 141():227-233. PubMed ID: 31522881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid effective dose calculation for raster-scanning
    Kopp B; Mein S; Tessonnier T; Besuglow J; Harrabi S; Heim E; Abdollahi A; Haberer T; Debus J; Mairani A
    Phys Med; 2021 Jan; 81():273-284. PubMed ID: 33353795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling secondary cancer risk ratios for proton versus carbon ion beam therapy: A comparative study based on the local effect model.
    Hufnagl A; Johansson G; Siegbahn A; Durante M; Friedrich T; Scholz M
    Med Phys; 2022 Aug; 49(8):5589-5603. PubMed ID: 35717591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modified microdosimetric kinetic model for relative biological effectiveness calculation.
    Chen Y; Li J; Li C; Qiu R; Wu Z
    Phys Med Biol; 2017 Dec; 63(1):015008. PubMed ID: 29240558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial.
    Habl G; Uhl M; Katayama S; Kessel KA; Hatiboglu G; Hadaschik B; Edler L; Tichy D; Ellerbrock M; Haberer T; Wolf MB; Schlemmer HP; Debus J; Herfarth K
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):435-443. PubMed ID: 27084659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spot-scanning hadron arc (SHArc) therapy: A proof of concept using single- and multi-ion strategies with helium, carbon, oxygen, and neon ions.
    Mein S; Kopp B; Tessonnier T; Liermann J; Abdollahi A; Debus J; Haberer T; Mairani A
    Med Phys; 2022 Sep; 49(9):6082-6097. PubMed ID: 35717613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of potential advantages of relevant ions for particle therapy: a model based study.
    Grün R; Friedrich T; Krämer M; Zink K; Durante M; Engenhart-Cabillic R; Scholz M
    Med Phys; 2015 Feb; 42(2):1037-47. PubMed ID: 25652516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can We Advance Proton Therapy for Prostate? Considering Alternative Beam Angles and Relative Biological Effectiveness Variations When Comparing Against Intensity Modulated Radiation Therapy.
    Underwood T; Giantsoudi D; Moteabbed M; Zietman A; Efstathiou J; Paganetti H; Lu HM
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):454-464. PubMed ID: 27084660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of modified microdosimetric kinetic model for relative biological effectiveness in proton therapy.
    Taghipour H; Taherparvar P
    Radiat Environ Biophys; 2022 Aug; 61(3):375-390. PubMed ID: 35699753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis.
    Widesott L; Pierelli A; Fiorino C; Lomax AJ; Amichetti M; Cozzarini C; Soukup M; Schneider R; Hug E; Di Muzio N; Calandrino R; Schwarz M
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1589-600. PubMed ID: 21167651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of Single Field Multi-Ion Particle Therapy Treatments.
    Kopp B; Mein S; Dokic I; Harrabi S; Böhlen TT; Haberer T; Debus J; Abdollahi A; Mairani A
    Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):194-205. PubMed ID: 31610250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probabilistic dose distribution from interfractional motion in carbon ion radiation therapy for prostate cancer shows rectum sparing with moderate target coverage degradation.
    Bridges D; Kawamura H; Kanai T
    PLoS One; 2018; 13(8):e0203289. PubMed ID: 30169520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetric and radiobiological impact of intensity modulated proton therapy and RapidArc planning for high-risk prostate cancer with seminal vesicles.
    Rana S; Cheng C; Zhao L; Park S; Larson G; Vargas C; Dunn M; Zheng Y
    J Med Radiat Sci; 2017 Mar; 64(1):18-24. PubMed ID: 27741379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximizing the biological effect of proton dose delivered with scanned beams via inhomogeneous daily dose distributions.
    Zeng C; Giantsoudi D; Grassberger C; Goldberg S; Niemierko A; Paganetti H; Efstathiou JA; Trofimov A
    Med Phys; 2013 May; 40(5):051708. PubMed ID: 23635256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion and validation of rectal constraints for prostate carcinoma receiving hypofractionated carbon-ion radiotherapy with a local effect model.
    Wang W; Li P; Sheng Y; Huang Z; Zhao J; Hong Z; Shahnazi K; Jiang GL; Zhang Q
    Radiat Oncol; 2021 Apr; 16(1):72. PubMed ID: 33849589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Comparison of the Effects of Interfractional Variations on Proton Therapy and Intensity Modulated Radiation Therapy for Prostate Cancer.
    Moteabbed M; Trofimov A; Sharp GC; Wang Y; Zietman AL; Efstathiou JA; Lu HM
    Int J Radiat Oncol Biol Phys; 2016 May; 95(1):444-453. PubMed ID: 26907917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.